CN107124884B - 双特异性her2和cd3结合分子 - Google Patents

双特异性her2和cd3结合分子 Download PDF

Info

Publication number
CN107124884B
CN107124884B CN201580051950.XA CN201580051950A CN107124884B CN 107124884 B CN107124884 B CN 107124884B CN 201580051950 A CN201580051950 A CN 201580051950A CN 107124884 B CN107124884 B CN 107124884B
Authority
CN
China
Prior art keywords
bispecific binding
binding molecule
seq
light chain
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580051950.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107124884A (zh
Inventor
张乃刚
安德烈斯·洛佩兹-阿尔百特罗
许红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN107124884A publication Critical patent/CN107124884A/zh
Application granted granted Critical
Publication of CN107124884B publication Critical patent/CN107124884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201580051950.XA 2014-07-25 2015-07-24 双特异性her2和cd3结合分子 Active CN107124884B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
US62/029,342 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (2)

Publication Number Publication Date
CN107124884A CN107124884A (zh) 2017-09-01
CN107124884B true CN107124884B (zh) 2022-11-01

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580051950.XA Active CN107124884B (zh) 2014-07-25 2015-07-24 双特异性her2和cd3结合分子

Country Status (15)

Country Link
US (2) US10519248B2 (enExample)
EP (1) EP3172236B1 (enExample)
JP (1) JP6871155B2 (enExample)
KR (1) KR102638104B1 (enExample)
CN (1) CN107124884B (enExample)
AU (1) AU2015292374B2 (enExample)
BR (1) BR112017001513A2 (enExample)
CA (1) CA2956014C (enExample)
ES (1) ES2832704T3 (enExample)
IL (1) IL250249B (enExample)
MX (1) MX386342B (enExample)
RU (1) RU2017105849A (enExample)
SG (1) SG11201700506TA (enExample)
WO (1) WO2016014942A1 (enExample)
ZA (1) ZA201701341B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CN107124884B (zh) 2014-07-25 2022-11-01 纪念斯隆-凯特林癌症中心 双特异性her2和cd3结合分子
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN109923128A (zh) 2016-11-15 2019-06-21 基因泰克公司 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
CA3051484A1 (en) * 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EA201992546A1 (ru) * 2017-04-24 2020-03-06 Мемориал Слоан Кеттеринг Кэнсер Сентер Средства на основе антител к cd33
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
CN118772288A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
CN112088169A (zh) * 2018-03-12 2020-12-15 纪念斯隆凯特琳癌症中心 双特异性结合剂及其用途
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
BR112020016997A2 (pt) * 2018-04-13 2021-01-19 F. Hoffmann-La Roche Ag Moléculas de ligação e de ácido nucleico isolada, vetor, célula hospedeira, métodos para produzir a molécula de ligação, para tratar um indivíduo com câncer e para regular positivamente ou prolongar a atividade de células t, composição farmacêutica e uso da molécula de ligação
CN112513081A (zh) * 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
JP2022510218A (ja) * 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
EP3894601A4 (en) * 2018-12-11 2023-01-11 The Translational Genomics Research Institute IDENTIFICATION OF HER2 MUTATIONS IN LUNG CANCER AND METHODS OF TREATMENT
BR112021016398A2 (pt) * 2019-02-22 2021-11-23 Memorial Sloan Kettering Cancer Center Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
CA3136251A1 (en) * 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113874399B (zh) * 2019-05-23 2025-07-11 维洛斯生物股份有限公司 抗ror1/抗cd3双特异性结合分子
WO2020264211A1 (en) * 2019-06-26 2020-12-30 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CA3187442A1 (en) * 2020-07-28 2022-02-03 Jeong A. PARK Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
WO2022081443A2 (en) * 2020-10-12 2022-04-21 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MX2023005130A (es) 2020-11-04 2023-05-25 Genentech Inc Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
CN117980888A (zh) * 2021-08-04 2024-05-03 阿布普罗公司 抗her2抗体及其用途
AU2022373303A1 (en) * 2021-10-20 2024-05-09 Memorial Hospital For Cancer And Allied Diseases Anti-tshr multi-specific antibodies and uses thereof
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
TW202519266A (zh) 2022-04-13 2025-05-16 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法
WO2024163964A2 (en) * 2023-02-04 2024-08-08 Imagion Biosystems, Inc. Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178137A1 (en) * 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
CN103648530A (zh) * 2011-05-08 2014-03-19 乐高化学生物科学股份有限公司 蛋白质-活性剂缀合物及其制备方法
WO2014079000A1 (en) * 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
CN103946371A (zh) * 2011-11-02 2014-07-23 味之素株式会社 用于分泌产生蛋白质的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO2005118635A2 (en) 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
RU2561457C2 (ru) 2007-04-03 2015-08-27 Эмджен Рисерч (Мьюник) Гмбх Cd3-эпсилон-связывающий домен с межвидовой специфичностью
ES2589769T3 (es) 2009-02-27 2016-11-16 Massachusetts Institute Of Technology Proteínas modificadas con alta afinidad por quelatos de DOTA
IL299365A (en) * 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
US20140170149A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
EP2895203A4 (en) * 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
BR112016001611B1 (pt) * 2013-07-25 2024-01-09 Cytomx Therapeutics, Inc Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
FI3083686T4 (fi) 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
CN107124884B (zh) 2014-07-25 2022-11-01 纪念斯隆-凯特林癌症中心 双特异性her2和cd3结合分子
US10988534B2 (en) 2015-02-09 2021-04-27 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
CA3051484A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648530A (zh) * 2011-05-08 2014-03-19 乐高化学生物科学股份有限公司 蛋白质-活性剂缀合物及其制备方法
WO2012178137A1 (en) * 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
CN103946371A (zh) * 2011-11-02 2014-07-23 味之素株式会社 用于分泌产生蛋白质的方法
WO2014079000A1 (en) * 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A modular IgG-scFv bispecific antibody topology;Kelly Davis Orcutt等;《Protein Engineering, Design & Selection》;20091217;第23卷(第4期);第221-228页 *
A novel bispecific antibody format enables simultaneous bivalent and monovalent coengagement of distinct target antigens;Gregory L. Moore等;《mAbs》;20111231;第3卷(第6期);第546-557页 *
Humanization of the murine anti-human CD3 monoclonal antibody OKT3;John R. Adair等;《Hum. Antibod. Hybridomas》;19941231;第5卷(第1-2期);第41-47页 *
Phase I/II Study of Treatment of Stage IV Breast Cancer with OKT3 x Trastuzumab–Armed Activated T Cells;Lawrence G. Lum等;《Clinical Breast Cancer》;20031231;第4卷(第3期);第212-217页 *
Targeting T Cells with Bispecific Antibodies for Cancer Therapy;Lawrence G. Lum等;《Biodrugs》;20111231;第25卷(第6期);第365-379页 *

Also Published As

Publication number Publication date
EP3172236B1 (en) 2020-09-30
IL250249B (en) 2021-04-29
US10519248B2 (en) 2019-12-31
IL250249A0 (en) 2017-03-30
US20170210819A1 (en) 2017-07-27
JP2017527274A (ja) 2017-09-21
AU2015292374B2 (en) 2020-09-03
ZA201701341B (en) 2021-05-26
JP6871155B2 (ja) 2021-05-12
BR112017001513A2 (pt) 2018-02-14
SG11201700506TA (en) 2017-02-27
US11987642B2 (en) 2024-05-21
MX386342B (es) 2025-03-18
ES2832704T3 (es) 2021-06-11
MX2017001031A (es) 2017-05-04
NZ729286A (en) 2023-12-22
WO2016014942A1 (en) 2016-01-28
EP3172236A1 (en) 2017-05-31
AU2015292374A1 (en) 2017-03-16
RU2017105849A (ru) 2018-08-29
CA2956014A1 (en) 2016-01-28
KR102638104B1 (ko) 2024-02-20
KR20170038835A (ko) 2017-04-07
CN107124884A (zh) 2017-09-01
CA2956014C (en) 2023-10-31
US20200199248A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
CN107124884B (zh) 双特异性her2和cd3结合分子
US20250179169A1 (en) Combination therapy for treatment of disease
JP7203446B2 (ja) Ｔｉｇｉｔ結合物質およびその使用法
KR20210015902A (ko) Psma 결합제 및 이의 용도
US11820832B2 (en) Bispecific HER2 and CD3 binding molecules
US20210324079A1 (en) Bispecific her2 and cd3 binding molecules
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
CA3051484A1 (en) Bispecific her2 and cd3 binding molecules
KR20160072268A (ko) 항-efna4 항체-약물 접합체
US11773160B1 (en) Immune-stimulating IL-2 fusion proteins
HK1238654B (en) Bispecific her2 and cd3 binding molecules
HK1238654A1 (en) Bispecific her2 and cd3 binding molecules
HK1181316A1 (en) Notch1 binding agents and methods of use thereof
HK1181316B (en) Notch1 binding agents and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment